Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bryoid
- Development stage
- Preclinical
- Lead developer
- Aphios
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Intramuscular, Intradermal, Transdermal, Intranasal, Topical, Rectal, Vaginal, Buccal, Sublingual, Intraperitoneal, Intra-arterial, Intrathecal, Ophthalmic, Parenteral
01
Overview
Bryoid refers to a family of novel bryostatin analogs developed by Aphios Corporation, derived from the marine bryozoan *Bugula neritina*. These complex cyclic macrolides, including specific compounds like Bryostatin-22 and Bryostatin-23, function as potent nanomolar activators of alpha-secretase and modulators of protein kinase C (PKC) isoforms, particularly PKC-delta and PKC-epsilon. By promoting the alpha-secretase-mediated cleavage of amyloid precursor protein (APP) into a non-toxic soluble form, Bryoids aim to prevent the formation of beta-amyloid plaques in Alzheimer's disease. Additionally, they are being investigated for their potential to purge latent HIV-1 reservoirs via NF-κB activation and for treating various cancers and neurodegenerative conditions such as Parkinson's disease and multiple sclerosis.
- Other names
- Bryoids
02
Targets
Protein kinase C family C1-domainPRKCD (Protein kinase C delta)ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)PRKCI (Protein kinase C iota)PRKCA (Protein kinase C alpha)
Beyond the preview
Go deeper on Bryoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bryoid.